论文部分内容阅读
目的:观察并探讨艾迪注射液与多西他赛(Docetaxel,DCT)、卡铂(Carboplatin,CP)化疗方案联合治疗非小细胞肺癌(Non-small cell lung cancer,NSCLC)的近期疗效和安全性。方法:选择2010年4月—2014年3月期间接诊的NSCLC患者78例,按照随机数字法将78例患者分为两组,观察组和对照组各39例,对照组给予DCT+CP化疗方案,观察组在对照组的基础上给予艾迪注射液治疗。随访并评价两组实体肿瘤近期疗效,治疗前后生存质量评分及不良反应发生情况。结果:观察组缓解率(CR+PR)为35.9%(14/39),对照组为30.8%(12/39),观察组缓解率明显高于对照组(P<0.05);两组治疗前生存质量评分各项相比,差异不具有统计学意义(P>0.05);治疗后,观察组生理功能、情感功能、社会功能得分明显高于对照组(P<0.05),而疲劳、疼痛和呕吐得分明显更低(P<0.05);观察组消化道反应、白细胞减少和血小板减少发生率分别为30.8%(12/39)、12.8%(5/39)和10.2%(4/39),对照组为38.5%(15/39)、30.8%(12/39)和15.4%(6/39),观察组血小板减少发生率明显低于对照组(P<0.05)。结论:艾迪注射液联合DCT+CP化疗方案治疗NSCLC疗效显著,可提升患者生活质量,且具有更高的安全性。
Objective: To observe and discuss the short-term curative effect and safety of combining Aidi Injection with Docetaxel (DCT) and carboplatin (CP) in the treatment of non-small cell lung cancer (NSCLC) Sex. Methods: Seventy-eight NSCLC patients were recruited from April 2010 to March 2014. 78 patients were divided into two groups according to the random number method. The control group and the observation group were given 39 cases of DCT plus CP chemotherapy Program, the observation group was given Aidi injection on the basis of the control group. Follow-up and evaluation of two groups of solid tumors in the short term efficacy, quality of life before and after treatment scores and adverse reactions. Results: The response rate (CR + PR) was 35.9% (14/39) in the observation group and 30.8% (12/39) in the control group, and the remission rate in the observation group was significantly higher than that in the control group (P <0.05) (P> 0.05). After treatment, the scores of physical function, emotional function and social function in the observation group were significantly higher than those in the control group (P <0.05), but the scores of fatigue, pain and the quality of life were not significantly different The vomiting score was significantly lower (P <0.05). The incidences of digestive tract reaction, leukopenia and thrombocytopenia in the observation group were 30.8% (12/39), 12.8% (5/39) and 10.2% (4/39) The control group was 38.5% (15/39), 30.8% (12/39) and 15.4% (6/39), respectively. The incidence of thrombocytopenia in the observation group was significantly lower than that in the control group (P <0.05). CONCLUSION: Aidi injection combined with DCT + CP chemotherapy has significant efficacy in treating NSCLC, which can improve the quality of life of patients with higher safety.